EP1527407A2 - Verfahren sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur analyse einer wirksamkeit eines pharmazeutischen präparats - Google Patents
Verfahren sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur analyse einer wirksamkeit eines pharmazeutischen präparatsInfo
- Publication number
- EP1527407A2 EP1527407A2 EP03790651A EP03790651A EP1527407A2 EP 1527407 A2 EP1527407 A2 EP 1527407A2 EP 03790651 A EP03790651 A EP 03790651A EP 03790651 A EP03790651 A EP 03790651A EP 1527407 A2 EP1527407 A2 EP 1527407A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical preparation
- signals
- influence
- computer
- neuronal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
Definitions
- the invention relates to an analysis of the effectiveness of a pharmaceutical preparation or medical preparation.
- the new drug to be approved goes through various (test) phases, phase 1 to phase 3, during which the effectiveness of the new drug to be approved in combating a specific disease must be demonstrated.
- side effects of the new drug to be approved as well as the effectiveness of the new drug to be approved are also compared with other correspondingly effective drugs.
- the efficacy tests are usually carried out by studies on test subjects to whom the new drug to be approved is administered.
- the effectiveness of the new drug is assessed on the basis of results from surveys, psychological tests and behavioral studies that are carried out with the test subjects.
- the previously known magnetic resonance imaging (also magnetic resonance imaging, abbreviated: MR) is an imaging method that generates sectional images of the human body without the use of stressful X-rays.
- the MR makes use of the behavior of the body tissue in a strong magnetic field. Pathological changes in the body tissue, for example in the brain or spinal cord, can be identified.
- BOLD signal Blood Oxygenation Level Dependent
- the result of the fMRI measurements shows the course of the activity of individual neuronal areas over a certain period of time, for example during cognitive processes as a result of certain perceptual processes or motor tasks.
- SEM Structure Equation Modeling
- the task of this analysis method described below is to identify the functional relationships between different brain areas described above in certain perception processes or motor tasks, in short the derivation of functional neuron structures for special tests.
- This known analysis method is based on a predefined model of a brain, i.e. a predefined brain architecture.
- the coupling matrix S has a (column / row) shape or shape defined in accordance with the given brain architecture.
- An activity pattern is evaluated using a statistical method, such as "Structural Equation Modeling", or SEM for short, which generates statistical properties or key figures, such as the coupling quantities. These characterize a complex state of excitation of the neuron structure and thus enable it the evaluation and assessment of the effectiveness of the pharmaceutical preparation.
- a neuronal model of the neuron structure is generated, which is reflected in a structure of the coupling sizes.
- the signals are evaluated using a method based on "Structural Equation Modeling" (SEM), the changed coupling sizes being determined.
- SEM Structuretural Equation Modeling
- a SEN is known from [6].
- the signals which can be analog or digital signals, can be determined by measurement, for example by measuring BOLD signals, or can also be read in from a memory or from a storage medium or from a D / A converter.
- fMRI BOLD signals from a subject are measured. These are then evaluated using the statistical method.
- Preparations can be completely different preparations or their composition of materials can vary. Differentiate, for example in such a way that active ingredient proportions in a preparation are increased or decreased.
- FIG. 3 sketch according to an exemplary embodiment, which describes a procedure for determining the effectiveness of a pharmaceutical preparation using an fMRI.
- FIG. 3 schematically shows the procedure or the conceptual interaction of various functional components in the determination and evaluation of an effectiveness of a pharmaceutical preparation using functional magnetic resonance imaging or magnetic resonance imaging (short: fMRI).
- FIG. 3 shows a device 310 for performing a functional magnetic resonance tomography or magnetic resonance tomography (short: fMRI), a functional magnetic resonance tomograph or magnetic resonance tomograph 310 (cf. FIGS. 1, 100).
- the drug to be evaluated in this case is a newly developed pharmaceutical 331 for the treatment of Alzheimer's.
- the pharmaceutical 331 is evaluated in the context of a clinical study 330.
- a study in an approval procedure for a new drug and a basic procedure for such a study, in particular the handling of test subjects and the administration of test preparations, is from [7] known.
- the present study comprises two stages:
- Tested here means that all study participants are each subjected to an fMRI.
- the fMRI measurements of both groups are evaluated as described below, with what are known as coupling variables being determined, among other things.
- the amount and nature of the changes i.e. the amount and type of changes in the values of the coupling sizes indicate a quantifiable effect or the effectiveness of the pharmaceutical being tested.
- the magnetic resonance tomograph 100 has a patient table 130 which can be moved into the tube 110 and on which a patient is supported during an examination.
- the magnetic resonance tomograph 100 has a control device 131, which enables the patient table 130 to be checked and controlled during the examination, for example a controlled insertion of the patient table 130 into the tube 120.
- the magnetic resonance tomograph 100 has a measuring device 140 for measuring BOLD signals (Blood Oxygenation Level Dependent), an associated evaluation device 141 for evaluating the measured BOLD signals, in this case a high-performance computer, and an operating or interaction device 142 for operating personnel as well as a display device 143 for displaying an examination result.
- BOLD signals Bood Oxygenation Level Dependent
- an associated evaluation device 141 for evaluating the measured BOLD signals
- an operating or interaction device 142 for operating personnel as well as a display device 143 for displaying an examination result.
- the neuronal activity in areas of the brain of a patient can be measured, analyzed and a diagnosis can be derived therefrom on the basis of the fMRI technique.
- the measuring device 140 measures the BOLD signal (Blood Oxygenation Level Dependent) in individual, selected areas of the patient's brain, which is related to the neuronal activity in the respective area.
- the result of such fMRI measurements shows the course of the activity of the individual areas over a certain period of time, for example during cognitive processes as a result of certain perceptual processes or motor tasks which are to be carried out by the patient during an examination.
- the fMRI measurements i.e. the BOLD signals measured in individual areas of the brain are analyzed.
- the new analysis method brain activity is determined in the form of corresponding activation patterns in the areas examined in the brain and / or relationships between activation patterns in the areas examined and from this direct conclusions can be drawn about "normal" activity patterns or excitation states in the brain as well as functional disorders in the brain and their causes won.
- the new analysis method provided by the evaluation device 140 is based on an expanded and more flexible model of the brain, the neuron structures in the brain and their behavior, in particular their interaction (FIGS. 3, 340), on the basis of which the measured BOLD signal is analyzed and is evaluated.
- ⁇ ⁇ ⁇ C ⁇ , .-., C L , ⁇ ⁇ , ..., ⁇ L , ⁇ , ..., ⁇ L)
- the optimal model parameters are determined using the maximum likelihood estimation [1] by optimizing or maximizing the probabilities (5) (240).
- the parameters to be taken into account for the optimization process are the parameters of the selected higher order statistical distribution, in this case the weighted sum of the normal distributions, the model parameters sought and the statistical quantities, in this case the mean ⁇ and the covariance ⁇ from (6), the relationships between the model parameters and the statistical distribution (5) were established.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10236630 | 2002-08-09 | ||
DE10236630 | 2002-08-09 | ||
PCT/DE2003/002497 WO2004021243A2 (de) | 2002-08-09 | 2003-07-24 | Verfahren sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur analyse einer wirksamkeit eines pharmazeutischen präparats |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1527407A2 true EP1527407A2 (de) | 2005-05-04 |
Family
ID=31968957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03790651A Withdrawn EP1527407A2 (de) | 2002-08-09 | 2003-07-24 | Verfahren sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur analyse einer wirksamkeit eines pharmazeutischen präparats |
Country Status (3)
Country | Link |
---|---|
US (1) | US20060106543A1 (de) |
EP (1) | EP1527407A2 (de) |
WO (1) | WO2004021243A2 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050197561A1 (en) * | 2004-03-05 | 2005-09-08 | Elsinger Catherine L. | System for detecting symptoms, determining staging and gauging drug efficacy in cases of Parkinson's disease |
US20050197560A1 (en) * | 2004-03-05 | 2005-09-08 | Rao Stephen M. | System for detecting symptoms, determining staging and gauging drug efficacy in cases of Alzheimer's disease |
US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
US10052497B2 (en) * | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
JP2009502140A (ja) | 2005-07-22 | 2009-01-29 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 光活性化陽イオンチャネルおよびその使用 |
US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US20090093403A1 (en) | 2007-03-01 | 2009-04-09 | Feng Zhang | Systems, methods and compositions for optical stimulation of target cells |
US8398692B2 (en) | 2007-01-10 | 2013-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US8401609B2 (en) | 2007-02-14 | 2013-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
US10035027B2 (en) * | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
ES2608498T3 (es) | 2008-04-23 | 2017-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sistemas, métodos y composiciones para la estimulación óptica de células diana |
CA2726128C (en) | 2008-05-29 | 2016-10-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell line, system and method for optical control of secondary messengers |
EP2303405A4 (de) * | 2008-06-17 | 2017-12-27 | The Board of Trustees of the Leland Stanford Junior University | Gerät und verfahren zur kontrolle der zellentwicklung |
US8956363B2 (en) | 2008-06-17 | 2015-02-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
WO2010006049A1 (en) | 2008-07-08 | 2010-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
NZ602416A (en) | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
JP5866332B2 (ja) | 2010-03-17 | 2016-02-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 感光性イオンを通過させる分子 |
CN106947741A (zh) | 2010-11-05 | 2017-07-14 | 斯坦福大学托管董事会 | 光活化嵌合视蛋白及其使用方法 |
AU2011323228B2 (en) | 2010-11-05 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of memory function |
CN110215614A (zh) | 2010-11-05 | 2019-09-10 | 斯坦福大学托管董事会 | 用于光遗传学方法的光的上转换 |
CA2816968C (en) | 2010-11-05 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-controlled cns dysfunction |
EP2635346B1 (de) | 2010-11-05 | 2017-03-29 | The Board of Trustees of the Leland Stanford Junior University | Optogenetische steuerung eines verhaltens in zusammenhang mit belohnungen |
US10568307B2 (en) | 2010-11-05 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
WO2013090356A2 (en) | 2011-12-16 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
AU2013222443B2 (en) | 2012-02-21 | 2017-12-14 | Circuit Therapeutics, Inc. | Compositions and methods for treating neurogenic disorders of the pelvic floor |
WO2014144409A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of behavioral state |
US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
AU2014260101B2 (en) | 2013-04-29 | 2018-07-26 | Humboldt-Universitat Zu Berlin | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
JP6621747B2 (ja) | 2013-08-14 | 2019-12-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疼痛を制御するための組成物及び方法 |
WO2016209654A1 (en) | 2015-06-22 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5372137A (en) * | 1993-01-19 | 1994-12-13 | The Mcw Research Foundation, Inc. | NMR local coil for brain imaging |
US6377833B1 (en) * | 1999-01-25 | 2002-04-23 | Douglas Albert | System and method for computer input of dynamic mental information |
DE19962848C2 (de) * | 1999-12-24 | 2003-03-27 | Forschungszentrum Juelich Gmbh | Echo-Planar-Bildgebungsverfahren |
US6893821B2 (en) * | 2000-05-05 | 2005-05-17 | The Regents Of The University Of California | Agents that modulate DNA-PK activity and methods of use thereof |
CA2451992C (en) * | 2001-05-15 | 2013-08-27 | Psychogenics Inc. | Systems and methods for monitoring behavior informatics |
US7546158B2 (en) * | 2003-06-05 | 2009-06-09 | The Regents Of The University Of California | Communication methods based on brain computer interfaces |
US20050153885A1 (en) * | 2003-10-08 | 2005-07-14 | Yun Anthony J. | Treatment of conditions through modulation of the autonomic nervous system |
-
2003
- 2003-07-24 EP EP03790651A patent/EP1527407A2/de not_active Withdrawn
- 2003-07-24 US US10/524,000 patent/US20060106543A1/en not_active Abandoned
- 2003-07-24 WO PCT/DE2003/002497 patent/WO2004021243A2/de not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2004021243A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004021243A2 (de) | 2004-03-11 |
WO2004021243A3 (de) | 2004-10-14 |
US20060106543A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1527407A2 (de) | Verfahren sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur analyse einer wirksamkeit eines pharmazeutischen präparats | |
DE102007057885B4 (de) | Verfahren zur Analyse von physiologischen Daten und Qualitätsprüfung der Messung unter Verwendung der Analyse der Hauptkomponenten | |
DE4134960A1 (de) | Verfahren zur ganzheitlichen analyse des gesundheitszustandes | |
Camchong et al. | Changes in resting functional connectivity during abstinence in stimulant use disorder: a preliminary comparison of relapsers and abstainers | |
DE102011115116A1 (de) | Verfahren zur Bewusstseins- sowie Schmerzüberwachung, Modul zur Analyse von EEG-Signalen und EEG-Narkosemonitor | |
DE112012001902T5 (de) | Vorrichtung, System und Verfahren zur Beurteilung der Wirksamkeit von Arzneistoffen anhand holistischer Analyse und Visualisierung von pharmakologischen Daten | |
EP1059875A1 (de) | Auswertesystem zur gewinnung diagnostischer informationen aus signalen und daten medizinischer sensorsysteme | |
DE10100441C2 (de) | Verfahren zum Betrieb eines Magnetresonanzgeräts bei Initiierung einer neuronalen Aktivität und Magnetresonanzgerät zum Durchführen des Verfahrens | |
EP1456798A2 (de) | Auswerten von mittels funktionaler magnet-resonanz-tomographie gewonnenen bildern des gehirns | |
DE102008021940A1 (de) | Stimulationsanordnung zur Messung der physiologischen Signalreaktivität | |
EP1175865B1 (de) | Kardiologisches Geräteimplantat ausgestattet mit einem Auswerteverfahren zur Bestimmung der zeitlichen Stationarität gemessener kardiologischer Signale | |
Chapman et al. | C145 as a short-latency electrophysiological index of cognitive compensation in Alzheimer's disease | |
DE212005000005U1 (de) | Vorrichtung zur adaptiven Datenanalyse | |
DE102016203940B4 (de) | MR-Bildgebung mit optimiertem Bildgebungsarbeitsablauf | |
EP1395940A2 (de) | Verfahren zur überwachung telemedizinischer gesundheitsdienstleistungen | |
WO2004021245A2 (de) | Verfahren und anordnung sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur analyse von neuronalen aktivitäten in neuronalen arealen | |
DE10105387C2 (de) | Verfahren zum Betrieb eines Magnetresonanzgeräts zur funktionellen Bildgebung sowie Magnetresonanzgerät zur Durchführung des Verfahrens | |
EP1527354A1 (de) | Verfahren und anordnung sowie computerprogramm mit programmcode-mitteln zur analyse von neuronalen aktivit ten in neuronalen arealen | |
Feng et al. | Different macaque brain network remodeling after spinal cord injury and NT3 treatment | |
WO2004021244A2 (de) | Verfahren und anordnung sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur analyse von neuronalen aktivitäten in neuronalen arealen | |
EP2318968A2 (de) | Verfahren zur überwachung des medizinischen zu standes eines patienten | |
WO2004021246A2 (de) | Verfahren und anordnung sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur ermittlung einer unregelmässigkeit in einer neuronenstruktur | |
DE10146263B4 (de) | Verfahren und Vorrichtung zur Auswertung von gemessenen periodischen oder quasi periodischen Signalen medizinischer Sensorsysteme | |
DE4110049C2 (de) | ||
Koyano et al. | Cascades of neuronal plasticity in the macaque visual cortex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041223 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
RBV | Designated contracting states (corrected) |
Designated state(s): CH DE FR GB LI |
|
17Q | First examination report despatched |
Effective date: 20061030 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DECO, GUSTAVO Inventor name: STETTER, MARTIN Inventor name: GALM, NORBERT |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070510 |